Alps Advisors Inc. raised its position in Agilent Technologies Inc (NYSE:A) by 13.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 19,379 shares of the medical research company’s stock after acquiring an additional 2,332 shares during the period. Alps Advisors Inc.’s holdings in Agilent Technologies were worth $1,485,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Trust Advisors LP increased its holdings in shares of Agilent Technologies by 27.8% during the 3rd quarter. First Trust Advisors LP now owns 502,441 shares of the medical research company’s stock worth $38,502,000 after acquiring an additional 109,369 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Agilent Technologies by 67.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 39,871 shares of the medical research company’s stock worth $3,056,000 after acquiring an additional 16,041 shares during the last quarter. Keybank National Association OH increased its holdings in shares of Agilent Technologies by 0.4% during the 3rd quarter. Keybank National Association OH now owns 59,694 shares of the medical research company’s stock worth $4,574,000 after acquiring an additional 229 shares during the last quarter. Tibra Equities Europe Ltd acquired a new position in shares of Agilent Technologies during the 3rd quarter worth approximately $1,019,000. Finally, Cantillon Capital Management LLC increased its holdings in shares of Agilent Technologies by 6.9% during the 3rd quarter. Cantillon Capital Management LLC now owns 4,216,472 shares of the medical research company’s stock worth $323,108,000 after acquiring an additional 271,249 shares during the last quarter.

Shares of NYSE A opened at $76.64 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.13 and a quick ratio of 1.72. The stock’s fifty day moving average price is $75.70 and its two-hundred day moving average price is $72.83. Agilent Technologies Inc has a one year low of $62.00 and a one year high of $82.27. The firm has a market cap of $23.38 billion, a price-to-earnings ratio of 27.47, a P/E/G ratio of 1.88 and a beta of 1.42.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The firm had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the firm posted $0.67 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, equities analysts anticipate that Agilent Technologies Inc will post 3.08 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Monday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.66%.

In related news, CEO Michael R. Mcmullen sold 24,635 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $77.50, for a total transaction of $1,909,212.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Heidi Fields sold 4,000 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $78.56, for a total value of $314,240.00. Following the sale, the director now owns 53,287 shares of the company’s stock, valued at $4,186,226.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,635 shares of company stock worth $2,507,293.

A has been the topic of a number of recent analyst reports. Piper Jaffray Companies boosted their target price on Agilent Technologies from $83.00 to $86.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. Needham & Company LLC boosted their target price on Agilent Technologies to $92.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Bank of America lowered Agilent Technologies from a “buy” rating to a “neutral” rating and set a $76.00 target price on the stock. in a report on Tuesday, July 16th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 target price on the stock. in a report on Monday, August 19th. Finally, Robert W. Baird reissued an “outperform” rating and set a $82.00 target price (up from $79.00) on shares of Agilent Technologies in a report on Thursday, August 15th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Agilent Technologies has a consensus rating of “Buy” and a consensus target price of $84.00.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: What is total return in investing?

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.